Skip to main content

Advertisement

Log in

Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment

  • Case Report
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Calciphylaxis occurs rarely in the absence of end stage renal disease. Predisposing factors for nonuremic calciphylaxis (NUC) include hyperparathyroidism, coagulopathies, connective tissue disease, liver disease, glucocorticoid use, and malignancy. Warfarin can facilitate vascular calcification by reducing vitamin K-dependent carboxylation of matrix-Gla proteins. An 86-year-old Caucasian woman with a history of polymyalgia rheumatica, two spontaneous deep venous thromboses (DVTs) and multiple fractures was treated with calcium, vitamin D, prednisone, and warfarin. The patient's low bone density was treated initially with estrogen, then oral bisphosphonate, which was discontinued due to upper gastrointestinal symptoms. Nasal calcitonin was initiated. After 10 years of calcitonin treatment, she was changed to teriparatide. Two months after initiating teriparatide, she developed lower extremity edema and painful erythematous nodular lesions on her calves bilaterally, that progressed to necrotic ulcers despite antibiotic therapy. Biopsy of the lesions showed calcification in the media of small blood vessels and subcutaneous fat with fat necrosis, consistent with calciphylaxis. Teriparatide was discontinued. Aggressive wound care, antibiotics, and intravenous zoledronic acid were initiated. With cessation of teriparatide therapy and intensive wound care, the patient's lesions resolved over 8 months. We report the first case of NUC precipitated by teriparatide therapy. Our patient had multiple underlying predisposing factors including a connective tissue disorder, glucocorticoid therapy, warfarin use, and possible underlying coagulopathy given her history of multiple DVTs. In such patients, alternative osteoporosis therapies may be preferred.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc of Nephrol: CJASN 3:1139–1143

    Article  Google Scholar 

  2. Bryant JHWW (1898) A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hosp Rep 55:17–20

    Google Scholar 

  3. Selye H, Gabbiani G, Strebel R (1962) Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 71:554–558

    Article  CAS  PubMed  Google Scholar 

  4. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  5. Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089, discussion 1089–1090

    Article  CAS  PubMed  Google Scholar 

  6. Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol: JASN 7:978–982

    CAS  PubMed  Google Scholar 

  7. Weenig RH (2008) Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 58:458–471

    Article  PubMed  Google Scholar 

  8. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579

    Article  PubMed  Google Scholar 

  9. Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dialysis 20:150–157

    Article  Google Scholar 

  10. Vedvyas C, Winterfield LS, Vleugels RA (2012) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67:e253–e260

    Article  PubMed  Google Scholar 

  11. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047–4054

    CAS  PubMed  Google Scholar 

  12. Asobie N, Wong E, Cook MG (2008) Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 33:342–344

    Article  CAS  PubMed  Google Scholar 

  13. Wallin R, Cain D, Sane DC (1999) Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. Thromb Haemost 82:1764–1767

    CAS  PubMed  Google Scholar 

  14. Howe AM, Webster WS (2000) Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 81:51–56

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Investig 112:357–366

    Article  PubMed Central  PubMed  Google Scholar 

  16. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81

    Article  CAS  PubMed  Google Scholar 

  17. Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67(6):e253–e260

    Article  PubMed  Google Scholar 

  18. Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217

    Article  PubMed  Google Scholar 

  19. Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ (2008) Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 23:387–389

    Article  CAS  PubMed  Google Scholar 

  20. Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA (2000) Is calciphylaxis best treated surgically or medically? Surgery 128:967–971, discussion 971–962

    Article  CAS  PubMed  Google Scholar 

  21. Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res: Off J Am Soc Bone Miner Res 2:135–142

    Article  CAS  Google Scholar 

  22. Schliep S, Schuler G, Kiesewetter F (2008) Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol: EJD 18:554–556

    CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. E. Sellmeyer.

Additional information

This work was partially supported by the NIH T32 training grant (#101776).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spanakis, E.K., Sellmeyer, D.E. Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment. Osteoporos Int 25, 1411–1414 (2014). https://doi.org/10.1007/s00198-013-2580-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-013-2580-6

Keywords

Navigation